# OnCo record paper-hess-ca19-9-response-chemotherapy-lancet-oncol-2008 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-hess-ca19-9-response-chemotherapy-lancet-oncol-2008/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-hess-ca19-9-response-chemotherapy-lancet-oncol-2008" ;
  schema:name "CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial"@en ;
  schema:description "In a randomised trial, a high CA 19-9 before treatment predicted shorter survival, but a 50% fall during chemotherapy did not mean living longer once the analysis was corrected, so a falling marker is not a valid substitute for survival."@en ;
  schema:url <https://onco.cc/key-papers/paper-hess-ca19-9-response-chemotherapy-lancet-oncol-2008/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s1470-2045(08)70001-9>, <https://pubmed.ncbi.nlm.nih.gov/18249033/> ;
  schema:sameAs <https://doi.org/10.1016/s1470-2045(08)70001-9> ;
  schema:datePublished "2008"^^xsd:gYear ;
  schema:author "Hess V, Glimelius B, Grawe P, et al." ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:terms <https://onco.cc/terms/ca19-9/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .